Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) Plus Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb (BMS)
In this trial, patients will be randomised into one of two cohorts. In Arm 1 patients will receive BMS-986213 (Relatlimab + Nivolumab) + investigator's choice chemotherapy on specified days. In Arm 2, patients will receive Nivolumab (alone) + investigator's choice chemotherapy on specified days.